Related Experiment Video
Updated: Oct 16, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Takshveer Singh1, Mortaza Fatehi Hassanabad1, Ali Fatehi Hassanabad1
1Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract:
Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary lung malignancies. NSCLC is often diagnosed at later stages and requires systemic therapies. Despite recent advances in surgery, chemotherapy, and targeted molecular therapies the outcomes of NSCLC remain disproportionately poor. Immunotherapy is a rapidly developing area in NSCLC management and presents opportunities for potential improvements in clinical outcomes. Indeed, different immunotherapeutics have been approved for clinical use in various settings for NSCLC. Their promise is especially poignant in light of improved survival and quality of life outcomes. Herein, we comprehensively review emerging NSCLC therapeutics. We discuss the limitations of such strategies and summarize the present status of various immunotherapeutic agents in key patient populations. We also examine the data from ongoing studies in immunotherapy and consider future areas of study, including novel inhibition targets, therapeutic vaccination, tumor genome modification, and improvements to drug delivery systems.
Insights
Immunotherapy offers new hope for non-small cell lung cancer (NSCLC) patients, improving survival and quality of life. This review covers current immunotherapeutics, limitations, and future directions in NSCLC treatment.
Area of Science:
- Oncology
- Immunology
- Medical Therapeutics
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
- Late-stage diagnosis and limited efficacy of current treatments necessitate novel therapeutic approaches.
Purpose of the Study:
- To comprehensively review emerging immunotherapeutics for NSCLC.
- To discuss current limitations and future research directions in NSCLC immunotherapy.
Main Methods:
- Systematic review of recent advancements in NSCLC immunotherapy.
- Analysis of clinical data for approved and investigational immunotherapeutic agents.
- Exploration of novel targets and therapeutic strategies.
Main Results:
- Immunotherapy has shown promise in improving survival and quality of life for NSCLC patients.
- Several immunotherapeutic agents are approved for clinical use in specific NSCLC settings.
- Ongoing studies are exploring new targets, vaccination, and drug delivery systems.
Conclusions:
- Immunotherapy represents a significant advancement in NSCLC management.
- Further research is crucial to overcome current limitations and optimize therapeutic outcomes.
- Future directions include novel targets, therapeutic vaccination, and improved drug delivery.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...